• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

GAS6/TAM 信号通路调控多发性骨髓瘤细胞中 MICA 的表达。

GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells.

机构信息

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Department of Biomedical Engineering, Emory University, Atlanta, GA, United States.

出版信息

Front Immunol. 2022 Jul 28;13:942640. doi: 10.3389/fimmu.2022.942640. eCollection 2022.

DOI:10.3389/fimmu.2022.942640
PMID:35967396
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9368199/
Abstract

NKG2D ligands play a relevant role in Natural Killer (NK) cell -mediated immune surveillance of multiple myeloma (MM). Different levels of regulation control the expression of these molecules at cell surface. A number of oncogenic proteins and miRNAs act as negative regulators of NKG2D ligand transcription and translation, but the molecular mechanisms sustaining their basal expression in MM cells remain poorly understood. Here, we evaluated the role of the growth arrest specific 6 (GAS6)/TAM signaling pathway in the regulation of NKG2D ligand expression and MM recognition by NK cells. Our data showed that GAS6 as well as MERTK and AXL depletion in MM cells results in MICA downregulation and inhibition of NKG2D-mediated NK cell degranulation. Noteworthy, GAS6 derived from bone marrow stromal cells (BMSCs) also increases MICA expression at both protein and mRNA level in human MM cell lines and in primary malignant plasma cells. NF-kB activation is required for these regulatory mechanisms since deletion of a site responsive for this transcription factor compromises the induction of promoter by BMSCs. Accordingly, knockdown of GAS6 reduces the capability of BMSCs to activate NF-kB pathway as well as to enhance MICA expression in MM cells. Taken together, these results shed light on molecular mechanism underlying NKG2D ligand regulation and identify GAS6 protein as a novel autocrine and paracrine regulator of basal expression of MICA in human MM cells.

摘要

NKG2D 配体在自然杀伤 (NK) 细胞介导的多发性骨髓瘤 (MM) 免疫监视中发挥重要作用。不同水平的调节控制这些分子在细胞表面的表达。许多致癌蛋白和 miRNA 作为 NKG2D 配体转录和翻译的负调节剂,但维持 MM 细胞中其基础表达的分子机制仍知之甚少。在这里,我们评估了生长停滞特异性 6 (GAS6)/TAM 信号通路在调节 NKG2D 配体表达和 NK 细胞对 MM 细胞的识别中的作用。我们的数据表明,GAS6 以及 MM 细胞中 MERTK 和 AXL 的耗竭导致 MIC A 下调和 NKG2D 介导的 NK 细胞脱颗粒抑制。值得注意的是,来自骨髓基质细胞 (BMSCs) 的 GAS6 也增加了人 MM 细胞系和原代恶性浆细胞中 MIC A 的蛋白和 mRNA 水平表达。NF-κB 激活是这些调节机制所必需的,因为该转录因子响应位点的缺失会损害 BMSCs 对启动子的诱导。因此,GAS6 的敲低降低了 BMSCs 激活 NF-κB 途径以及增强 MM 细胞中 MIC A 表达的能力。总之,这些结果阐明了 NKG2D 配体调节的分子机制,并确定 GAS6 蛋白是人类 MM 细胞中 MIC A 基础表达的新型自分泌和旁分泌调节剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d331/9368199/0b1a945948b8/fimmu-13-942640-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d331/9368199/4ae0fa46f352/fimmu-13-942640-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d331/9368199/3bc40ab3457a/fimmu-13-942640-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d331/9368199/d99ee022a6a5/fimmu-13-942640-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d331/9368199/21f0afe80f3f/fimmu-13-942640-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d331/9368199/0b1a945948b8/fimmu-13-942640-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d331/9368199/4ae0fa46f352/fimmu-13-942640-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d331/9368199/3bc40ab3457a/fimmu-13-942640-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d331/9368199/d99ee022a6a5/fimmu-13-942640-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d331/9368199/21f0afe80f3f/fimmu-13-942640-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d331/9368199/0b1a945948b8/fimmu-13-942640-g005.jpg

相似文献

1
GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells.GAS6/TAM 信号通路调控多发性骨髓瘤细胞中 MICA 的表达。
Front Immunol. 2022 Jul 28;13:942640. doi: 10.3389/fimmu.2022.942640. eCollection 2022.
2
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.抑制溴结构域和额外末端(BET)蛋白可增加NKG2D配体MICA的表达,并增强多发性骨髓瘤细胞对自然杀伤(NK)细胞介导的细胞毒性的敏感性:cMYC-IRF4-miR-125b相互作用的作用
J Hematol Oncol. 2016 Dec 1;9(1):134. doi: 10.1186/s13045-016-0362-2.
3
Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.肝 X 受体的激活通过不同的分子机制上调多发性骨髓瘤中 NKG2D 配体 MICA 和 MICB 的表达。
FASEB J. 2019 Aug;33(8):9489-9504. doi: 10.1096/fj.201900319R. Epub 2019 May 24.
4
Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.NEDD8-激活酶抑制在多发性骨髓瘤中的免疫调节作用:NKG2D 配体的上调和对自然杀伤细胞识别的敏感性。
Cell Death Dis. 2021 Sep 4;12(9):836. doi: 10.1038/s41419-021-04104-w.
5
Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.热休克蛋白90抑制剂可增加多发性骨髓瘤细胞上MHC I类相关链A和B配体的表达及其触发自然杀伤细胞脱颗粒的能力。
J Immunol. 2009 Oct 1;183(7):4385-94. doi: 10.4049/jimmunol.0901797. Epub 2009 Sep 11.
6
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.免疫调节药物(IMiDs)将IKZF-1/3和IRF4作为多发性骨髓瘤中自然杀伤细胞激活配体表达的新型负调节因子。
Oncotarget. 2015 Sep 15;6(27):23609-30. doi: 10.18632/oncotarget.4603.
7
Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing.细胞外囊泡传递 MIC 和 ULBP 配体介导的多发性骨髓瘤细胞的交叉染色促进 NK 细胞杀伤。
Int J Mol Sci. 2023 May 30;24(11):9467. doi: 10.3390/ijms24119467.
8
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.HLA I类分子、NKG2D和自然细胞毒性受体调节自然杀伤细胞对多发性骨髓瘤细胞的识别。
Blood. 2005 Jan 1;105(1):251-8. doi: 10.1182/blood-2004-04-1422. Epub 2004 Aug 24.
9
Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3.抑制糖原合酶激酶-3可增加多发性骨髓瘤细胞中 NKG2D 配体 MICA 的表达,并增加其对 NK 细胞介导的细胞毒性的敏感性:STAT3 的作用。
J Immunol. 2013 Jun 15;190(12):6662-72. doi: 10.4049/jimmunol.1201426. Epub 2013 May 17.
10
Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance.急性与慢性暴露于细胞外囊泡相关的 MIC A 对 NK 细胞功能的影响:在癌症免疫监视中的双重作用。
J Extracell Vesicles. 2022 Jan;11(1):e12176. doi: 10.1002/jev2.12176.

引用本文的文献

1
STAMBPL1/TRIM21 Balances AXL Stability Impacting Mesenchymal Phenotype and Immune Response in KIRC.STAMBPL1/TRIM21平衡AXL稳定性,影响肾透明细胞癌的间充质表型和免疫反应。
Adv Sci (Weinh). 2025 Jan;12(1):e2405083. doi: 10.1002/advs.202405083. Epub 2024 Nov 11.
2
The Role of TAM Receptors in Bone.TAM 受体在骨中的作用。
Int J Mol Sci. 2023 Dec 23;25(1):233. doi: 10.3390/ijms25010233.
3
Role of NF-κB Signaling in the Interplay between Multiple Myeloma and Mesenchymal Stromal Cells.NF-κB 信号在多发性骨髓瘤与间充质基质细胞相互作用中的作用。

本文引用的文献

1
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.NKG2D-CAR 修饰的自然杀伤细胞能有效靶向多发性骨髓瘤。
Blood Cancer J. 2021 Aug 14;11(8):146. doi: 10.1038/s41408-021-00537-w.
2
Hijacking TYRO3 from Tumor Cells via Trogocytosis Enhances NK-cell Effector Functions and Proliferation.通过细胞吞噬作用从肿瘤细胞中劫持 TYRO3 可增强 NK 细胞的效应功能和增殖。
Cancer Immunol Res. 2021 Oct;9(10):1229-1241. doi: 10.1158/2326-6066.CIR-20-1014. Epub 2021 Jul 29.
3
Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression.
Int J Mol Sci. 2023 Jan 17;24(3):1823. doi: 10.3390/ijms24031823.
多发性骨髓瘤中的骨髓间充质基质细胞:它们作为骨髓瘤进展的积极促成因素的作用
Cancers (Basel). 2021 May 22;13(11):2542. doi: 10.3390/cancers13112542.
4
Myeloma natural killer cells are exhausted and have impaired regulation of activation.骨髓瘤自然杀伤细胞功能耗竭,激活调节受损。
Haematologica. 2021 Sep 1;106(9):2522-2526. doi: 10.3324/haematol.2020.277525.
5
The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.骨髓微环境在多发性骨髓瘤中恶性浆细胞生长和发育中的作用。
Int J Mol Sci. 2021 Apr 24;22(9):4462. doi: 10.3390/ijms22094462.
6
TAM Receptor Inhibition-Implications for Cancer and the Immune System.TAM 受体抑制作用——对癌症和免疫系统的影响
Cancers (Basel). 2021 Mar 10;13(6):1195. doi: 10.3390/cancers13061195.
7
Facts and Hopes in Multiple Myeloma Immunotherapy.多发性骨髓瘤免疫治疗的现状与展望。
Clin Cancer Res. 2021 Aug 15;27(16):4468-4477. doi: 10.1158/1078-0432.CCR-20-3600. Epub 2021 Mar 26.
8
Signaling Pathway Mediating Myeloma Cell Growth and Survival.介导骨髓瘤细胞生长与存活的信号通路
Cancers (Basel). 2021 Jan 8;13(2):216. doi: 10.3390/cancers13020216.
9
NK cell-based cancer immunotherapy: from basic biology to clinical development.基于自然杀伤细胞的癌症免疫疗法:从基础生物学到临床开发。
J Hematol Oncol. 2021 Jan 6;14(1):7. doi: 10.1186/s13045-020-01014-w.
10
Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.靶向 NK 细胞抑制性受体的多发性骨髓瘤精准免疫治疗。
Front Immunol. 2020 Nov 12;11:575609. doi: 10.3389/fimmu.2020.575609. eCollection 2020.